Pcn89 - Cost –Effectiveness Analysis of Pertuzumab as First Line Neoadjuvant Treatment Option for Patients Her2 + Breast Cancer in Republic of Macedonia
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.171
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV